As Australia’s population ages, it is expected that the number of people with multiple chronic conditions (multimorbidity) will increase. Studies have shown that multimorbidity is associated with reduced quality of life for patients and increased demand on health resources, complexity of care and patient mortality. Similarly to many health care systems around the world, Australia’s secondary and tertiary health care has a single disease focus (e.g., diabetes mellitus or mental health). However, the complexity of care in managing patients with multiple chronic conditions, often with competing demands, is best handled in primary care by general practitioners (GPs).

This paper reports on the proportion of patients with multiple chronic conditions at GP encounters, using data from a 2008–2009 BEACH sub-study that measured the prevalence of chronic conditions. Of the 8707 patients sampled from 290 GPs, approximately half (47.4%, 95% CI: 45.2–49.6) had two or more chronic conditions. Figure 1 clearly shows that the proportion of patients with multiple chronic conditions at encounters rises significantly with age; about 90% of patients aged 80 years or more had two or more chronic conditions, while nearly 30% had seven or more.

This study has shown that the prevalence of multiple chronic conditions in patients does increase with patient age, and that a significant proportion of older patients have seven or more chronic conditions. With the ageing of the population, more than half of GP encounters will soon be with patients who have multiple chronic conditions. This suggests that we should reconsider our current health care system’s focus on single disease, and provides further evidence that in the future Australia will need to maintain a strong primary health care system, with GPs having a central role.

Authors
Christopher Harrison, Helena Britt, Graeme Miller and Joan Henderson,
Family Medicine Research Centre, University of Sydney, NSW.
Competing interests: None.
Provenance and peer review: Commissioned; not peer reviewed.

Acknowledgements
The authors thank the GP participants in the BEACH program and all members of the BEACH team. Financial contributors to BEACH between 2008 and 2010: Abbott Australasia; AstraZeneca Pty Ltd (Australia); Australian Government Department of Health and Ageing; Australian Government Department of Veterans’ Affairs; Australian Institute of Health and Welfare; Janssen-Cilag Pty Ltd; Merck, Sharpe and Dohme (Australia) Pty Ltd; National Prescribing Service; Novartis Pharmaceuticals Australia Pty Ltd; Pfizer Australia; Sanofi-Aventis Australia Pty Ltd; Wyeth Australia Pty Ltd.

References